BENTA Lyon in the news

Benta Pharma acquired Milan-based NerPharMa to expand its European manufacturing capabilities and become a fully integrated multinational CDMO.

Benta Pharma expanded its European manufacturing capabilities by acquiring NerPharMa, enhancing its multinational CDMO platform.

Benta Lyon expands its pharmaceutical manufacturing capabilities by acquiring Italian oncology drug producer NerPharMa.

Benta acquired Italian CDMO NerPharMa to boost its oncology and complex therapy manufacturing capabilities in Europe.

Benta Lyon is expanding from generic human pharmaceuticals into veterinary medicine by partnering to produce a critical veterinary drug and developing a regional supply chain.

Benta Lyon is boosting local pharmaceutical production in Auvergne-Rhône-Alpes by relaunching key drugs, expanding into sterile and veterinary medicines, and building local supply chains.

Benta is investing 5 million euros to add a sterile vial production line at its Lyon site, aiming for 2 million units annually by early 2026.

Benta is expanding its pharmaceutical manufacturing in Lyon with a new sterile vial production line to support veterinary and human medicine relocalization projects.

Benta Lyon is accelerating growth in generic pharmaceuticals by acquiring Stratégie Santé to enhance regulatory expertise and aims to expand its product range and revenue significantly by 2026.

Ananda Scientific and Benta SAS agreed to collaborate on developing and distributing a new PTSD treatment in Europe and MENA, combining clinical development and manufacturing expertise.

Benta Lyon acquires Stratégie Santé to boost expertise and accelerate growth in generic pharmaceutical production, targeting 80 generics and €30M revenue by 2026.

Benta Lyon is investing €5 million to start sterile pharmaceutical production by 2026, expanding its contract manufacturing and generics business.

Benta Lyon acquired Stratégie Santé to expand its regulatory and development services in pharmaceuticals.

Melchior santé animale is relocating production of a niche veterinary drug for calves to Benta Lyon, investing heavily to produce and export it globally while building a regional colostrum supply chain.

Benta Lyon has revived its French generic drug production with new investments and a focus on essential medicines, aiming to increase capacity and compete internationally.

Damien Parisien, executive general manager of Benta Lyon, appeared on a Lyon business show to discuss the company's activities and local economy.

Benta Lyon is investing one million euros, supported by France 2030, to relocalize paracetamol production in Saint-Genis-Laval.

Benta Lyon has offered 850 million euros to acquire Biogaran, the French generic drug leader, amid government concerns over foreign takeovers and its own financial challenges.

Benta Lyon has made a leading French bid to acquire Biogaran, France's top generic drug maker, with government vigilance to ensure production remains domestic.

Benta Lyon is reportedly preparing a nearly 1 billion euro bid to acquire Biogaran, France's top generic drug maker, while expanding its own pharmaceutical production.